KLEMP WALTER V 4

What Happened

Walter V. Klemp, CEO, President and a director of Moleculin Biotech (MBRX), had restricted stock units (RSUs) convert into 510 shares of common stock (150 shares on June 20, 2026 and 360 shares on June 22, 2026). To satisfy tax withholding on the vesting, the company withheld 125 shares (37 shares at $2.88/share and 88 shares at $3.12/share), representing about $382 in value; the net shares issued to him were 385. The transactions are reported as conversions/exercises of derivative awards (code M) with share withholding for taxes (code F).

Key Details

• Transaction dates: June 20, 2026 (150 RSUs converted; 37 shares withheld) and June 22, 2026 (360 RSUs converted; 88 shares withheld).
• Withheld shares and amounts: 37 shares @ $2.88 = $107; 88 shares @ $3.12 = $275; total withheld ≈ $382.
• Gross RSUs converted: 510; net shares received by Klemp: 385.
• Footnotes: F1/F2 indicate 1:1 RSU-to-common conversion and shares were withheld to pay taxes; F3 and F4 reference the original RSU grants (600 RSUs granted 6/20/2022; 1,439 RSUs granted 6/22/2023, each vesting in four annual installments).
• Beneficial ownership note (F5): filing references 250,002 shares underlying Series E warrants.
• Filing date: Form 4 filed June 24, 2026 covering June 20–22 transactions. Form 4s are typically due within two business days of the transaction; this filing was submitted a few days later.

Context

These entries reflect routine vesting and conversion of RSU awards rather than open‑market buying or selling. The derivative entries shown at $0 indicate conversion of awards (no cash exercise price). Withholding of shares to cover tax obligations is common and does not necessarily indicate a change in the insider's view of the company.